Blaas- en urinewegentumoren
EFFORT Trial
Phase II prospective trial to evaluate the impact of 18FFDG-PET-CT in stratifying patients with primary muscle invasive bladder cancer and adapting the treatment accordingly.
- Inclusion criteria: Patients diagnosed with muscle invasive bladder cancer without distant metastasis on conventional imaging (CT chest, abdomen and pelvic MRI) and who are candidates for neoadjuvant chemotherapy and radical curative treatment.
- Local site Principal Investigator (Urology): prof. dr. Maarten Albersen
- Sub-investigator (Nuclear Medicine): prof. dr. Karolien Goffin
- Sub-investigator (Radiotherapy): prof. dr. Gert De Meerleer
- More information: dr. Loïc Baekelandt (PhD) via loic.baekelandt@uzleuven.be or 016 344722
TAR-210 MoonRISe-1
Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer
- Inclusion criteria: IR-NMBC papillary disease Ta LG/G1 – recurrent OR Ta LG/G1 - primary and multifocal or primary and ≥ 3cm OR Ta G2 - primary or recurrent. With ≥ 1 of the following risk factors: Multiple Ta LG tumors, Solitary LG tumor > 3cm, Early recurrence of LG tumor (<1Y), Frequent recurrence (>1 per Y) and/or Recurrence after prior intravesical chemotherapy Local site Principal.
- Exclusion criteria: Received intravesical chemotherapy within 6 months of current diagnosis, received prior intravesical treatment with immunotherapy including BCG within 2 years prior to randomization, received prior treatment with an FGFR inhibitor.
- Investigator: prof. dr. Steven Joniau
- Sub-investigator (Urology): prof. dr. Ben Van Cleynenbreugell
- More information: NCT06319820
Blaaspijnsyndroom
Er zijn momenteel geen studies beschikbaar.
Niertumoren
Er zijn momenteel geen studies beschikbaar.
Overactieve blaas
Er zijn momenteel geen studies beschikbaar.
Penistumoren
Er zijn momenteel geen studies beschikbaar.
Prostaattumoren
EvoPAR-Prostate01
A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of novel PARP inhibitor AZD5305 in Combination with Physician’s Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer
- Inclusion criteria: mCSPC (adenocarcinoma), de novo or recurrent, with ≥ 1 bone lesion and/or ≥ 1 soft tissue lesion on conventional imaging (bone scan, CT/MRI). ADT with a GnRH analogue < 4 months with no radiographic evidence of disease progression or rising PSA levels. Participant must remain on ADT and be a candidate for treatment with an NHA (Abi, Daro, Enza).
- Local site Principal Investigator: prof. dr. Steven Joniau
- Sub-investigator (Urology): dr. Alexander Giesen
- More information: NCT06120491
ARASTEP
A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer
- Inclusion criteria: High-risk BCR after RP followed by adjuvant RT or salvage RT or after RP in participants who are unfit for adjuvant RT or salvage RT or after Primary RT. nmCSPC (adenocarcinoma) according to conventional imaging. PSADT < 12months.
- Local site Principal Investigator: prof. dr. Steven Joniau.
- Sub-investigator (Urology): dr. Alexander Giesen
- More information: NCT05794906.
Testistumoren
Er zijn momenteel geen studies beschikbaar.
Urinaire incontinentie
COLD INDUCED
Diagnostic tool and therapeutic strategy for acute cold-induced urgency (ACIU) part 2: optimizing the protocol
- Inclusion criteria: All patients with an overactive bladder for which a Urodynamic investigation is scheduled. Note that patients with prior pelvic floor surgery, neurological disorder or peripheral neuropathy are excluded from the study.
- Local site Principal Investigator: prof. dr. Wouter Everaerts
- Sub-investigator: prof. dr. Frank Van der Aa
Urinaire retentie
Er zijn momenteel geen studies beschikbaar.
Urineweg-infecties
MINUS Trial
Multicentric study on Infections of the Urinary tract after Stent removal
- Inclusion criteria: Patients, 18 years of age and older who receive a ureteral stent during any endoscopic procedure will be approached to participate in the study
- Local site Principal Investigator: dr. Carl Van Haute
- Sub-investigator (Urology): prof. dr. Ben Van Cleynenbreugel
- More information: NCT05329883
Questions
For more information, please contact trial urology.
- Email: urologie.trial@uzleuven.be
- Phone: +3216348345